Topics

Lilly Expands Migraine Franchise With Reyvow Approval

14:09 EDT 11 Oct 2019 | SCRIP

Reyvow gives Lilly a second MOA in migraine, following the anti-CGRP biologic Emgality, and adds an acute therapy to the...

      

Related Stories

 

Original Article: Lilly Expands Migraine Franchise With Reyvow Approval

NEXT ARTICLE

More From BioPortfolio on "Lilly Expands Migraine Franchise With Reyvow Approval"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...